3 Analysts Reiterate Buy Rating On Splunk

 | Nov 30, 2016 03:14PM ET

Here are today’s top Wall Street analyst ratings where finbox.io’s unbiased fair value estimates support the recommendation.h3 Top Upgrades and Buy Ratings/h3

  • Aegis initiated coverage on Globus Medical (NYSE:GMED) at Buy and set a $31 price target. Ten valuation models conclude an intrinsic value closer to $28 per share which still implies over 25% upside.